Aditya Bhattacharji

Aditya Bhattacharji
Aditya Bhattacharji manages Eurasia Group's (www.eurasiagroup.net) healthcare analysis, advising multinational healthcare and life sciences firms on the risks and opportunities stemming from health policy, particularly in emerging markets. He addresses a variety of issues including healthcare reform, innovation, drug pricing, market access, and public health crises, as well as their intersection with global macro themes. Aditya, who holds a master's degree in biohazardous threat agents and emerging infectious diseases from Georgetown University and a bachelor's degree in biology from the University of Pennsylvania, previously studied health policy, concentrating on infectious disease, and participated in private and public sector symposia and …
Aditya Bhattacharji manages Eurasia Group's (www.eurasiagroup.net) healthcare analysis, advising multinational healthcare and life sciences firms on the risks and opportunities stemming from health policy, particularly in emerging markets. He addresses a variety of issues including healthcare reform, innovation, drug pricing, market access, and public health crises, as well as their intersection with global macro themes.

Aditya, who holds a master's degree in biohazardous threat agents and emerging infectious diseases from Georgetown University and a bachelor's degree in biology from the University of Pennsylvania, previously studied health policy, concentrating on infectious disease, and participated in private and public sector symposia and simulations addressing public health emergencies. He oversaw life sciences research projects at Thomas Jefferson University and Monell Chemical Senses Center, where he employed pharmacology and biophysics to study alcohols and anaesthetics. Aditya has published his findings in a number of peer-reviewed periodicals, as well as a chapter in the International Congress Series on mechanisms of anaesthesia. He is a member of a number of professional organizations including One Health Academy and EcoHealth Alliance. In his free time, he participates in autocross racing.


See more

Articles: Aditya Bhattacharji

Coronavirus Poised to Undermine China’s Healthcare Miracle

China / Eurasia Group’s Aditya Bhattacharji examines the unfolding coronavirus outbreak, the prospects for China’s political and economic stability, and how healthcare firms should think about the path forward. China appears to be ground zero for a public health experiment with no recent analogues. The situation—in terms of social and economic dislocation—deteriorates daily, and represents the most…

The US in 2020: Structural Constraints to Rein in Political Enthusiasm for Healthcare

USA / Eurasia Group’s Aditya Bhattacharji examines the stalling of healthcare reforms in the US and what changes to US healthcare it is realistic to expect.   Pharma is unlikely to be frog-marched by sweeping federal initiatives, but more incremental changes are likely With anti-pharma sentiment raging at the end of 2018, it seemed all but certain…

Three More Key Issues for Pharma: Regulatory Assertiveness, Climate Change & India’s Health Policy Renaissance

Opinion / Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be cognizant of: the world’s leading drug regulators becoming increasingly strident and active beyond national borders; the impact that greater awareness and work on climate change could have on the industry; and the risks surrounding new health regulation in India.…

Three Key Political Issues for Pharma: Protests, Pricing & India’s Modicare

Opinion / This month, Aditya Bhattacharji takes stock of three political issues that are dominating Eurasia Group’s conversations with pharmaceutical firms: global protests, drug pricing, and India’s “Modicare” milestone.    Protests First, the rash of protests unfolding across parts of the Middle East, Asia, and Latin America has piqued firms’ attention—not just in terms of short term…

Regulatory & Legal Affairs: Two Growth Areas for Pharma

Opinion / Within the pharmaceutical space, Eurasia Group’s Aditya Bhattacharji expects politics to drive significant changes in regulatory and legal affairs. He explains how the evolving dynamics can be characterized by two themes.   Regulatory Right-Sizing The status quo is highly unlikely to hold in the regulatory space. The growing and largely uncharted nexus between healthcare and…

The Three Top Political Issues for Big Pharma

Opinion / Eurasia Group’s Aditya Bhattacharji and Sarah Hassan identify and unpack the top three political and policy issues that multinational pharmaceutical firms are currently focusing on.   Issue One: The Global Economy Over the past month, one theme stood out at both the central bankers’ confab in Jackson Hole, Wyoming and the G7 summit in Biarritz,…

The USA’s Safe Importation Action Plan: Trump’s Pharma ‘Sourcery’ has its Limits

USA / In a bid to make tangible progress on the issue of lowering prescription drug pricing before the 2020 presidential election, the Trump administration is planning to import cheaper medicines from Canada and elsewhere. However, as the Eurasia Group’s Aditya Bhattacharji and Sandra Yamin Namoos outline, the proposed plan’s impact on US drug prices stands to…

US-China Tensions Heating Up in the Life Sciences

USA / Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry.   Biotech [is the] new frontier for US-China tensions The G20 gathering in Osaka at the end of June was, overall, less tense than other multilateral fora over the past couple of years. One…

Europe: Political Complexity Bodes Poorly for Pharma

Opinion / Aditya Bhattacharji takes a look at the potentially damaging impact of political uncertainty across Europe – including the impending exit of the UK from the European Union – on pharmaceutical firms across the continent.   The right-leaning parties that will play a more prominent role in European politics are even less likely to support pan-EU…

Change is Coming for Healthcare

Opinion / Aditya Bhattacharji examines whether current healthcare models are truly fit for purpose and how healthcare is becoming a more politicised issue globally.   Globally, the healthcare sector is entering a lengthy period of heightened introspection. That process has been turbocharged by the resurgence of healthcare as a dominant social and political issue in the US—the…

Malaysia’s MYSalam Low-Income Healthcare Programme: A Modest Proposal

Malaysia / Eurasia Group’s Aditya Bhattacharji discusses the relatively modest scope of Malaysia’s recently-launched ‘MYSalam’ scheme; a healthcare programme which aims to provide coverage to the country’s bottom 40 percent of earners.   For the time being, the outlook for the private sector, including for pharmaceutical firms, is good Another populist government, another swing at healthcare reform.…

India Healthcare: “Modicare” Lives On

India / Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s ambitious healthcare insurance scheme, “Modicare” and delves into some of its critical challenges and associated opportunities for private players.   In theory, India’s states will be able to fine tune Modicare’s implementation to meet their local needs. But decentralization breeds…

China Healthcare in 2019: Sprinting a Marathon

China / Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the Year of the Pig, 2019.    China approved a record 48 new drugs last year, despite a significant organizational restructuring. 2019 is shaping up to…

Healthcare Politics in 2019

Opinion / Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In this article, he gives his predictions for the political landscape in healthcare for 2019.  The challenges for firms are painfully apparent—there is bipartisan support in the US to lower drug prices, a pervasive sense that traditional advocacy methods are failing in today’s political climate, and most importantly, the absence…

Gene-modified Babies in China Highlight Regulatory Concerns of CRISPR

Genomics / Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis and Kevin Allison is the director of geo-technology. Together they look at last week’s shock revelation of two CRISPR* babies who were born in China and the added tensions this might cause with the USA.    Aside from the immediate implications for US-China strategic competition, the revelations are jump-starting a global…

Nationalism & Populism: A Roadblock for Global Pharma

UK / Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In his second piece for PharmaBoardroom, Aditya examines the dangers of nationalism and populism for the private sector.   The biggest global risk I see is with active pharmaceutical ingredients, most of which come from China, which has been at the centre of trade tensions, with no signs of receding.…

Healthcare needs a new prescription

Medtech / Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. He calls for healthcare to be given a new prescription. But, will the private sector write it?   The UK’s National Health Service has crippling sustainability challenges.   With many firms in the midst of or preparing for annual strategic planning sessions, it feels appropriate to take a step back…

See more